Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News reported Tuesday.
This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.
Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。